首页|阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效分析

阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效分析

扫码查看
目的 探讨对冠心病患者使用曲美他嗪联合阿托伐他汀治疗的效果。方法 60 例冠心病患者,依据随机数字表法分为对照组和观察组,每组 30 例。对照组在常规干预基础上加用曲美他嗪治疗,观察组在对照组基础上加用阿托伐他汀治疗。对比两组临床效果、心功能指标[左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)]以及血液流变学指标(全血低切粘度、全血高切粘度、血浆粘度)。结果 观察组与对照组的总有效率分别为 93。33%、73。33%,与对照组对比,观察组的总有效率显著更高(P<0。05)。与对照组的血浆粘度(1。63±0。05)mPa·s、全血低切粘度(9。12±0。42)mPa·s、全血高切粘度(6。15±0。24)mPa·s对比,观察组治疗后的血浆粘度(1。45±0。04)mPa·s、全血低切粘度(7。36±0。22)mPa·s、全血高切粘度(5。22±0。17)mPa·s均较低(P<0。05)。与对照组的LVEF(41。62±9。42)%、LVEDD(63。30±7。21)mm、LVESD(51。24±8。10)mm对比,观察组治疗后的LVEF(47。69±12。08)%更高,LVEDD(59。38±6。65)mm、LVESD(46。53±7。27)mm均更小(P<0。05)。结论 对冠心病患者行阿托伐他汀联合曲美他嗪治疗可取得确切的临床疗效,并有助于心功能指标与血液流变学指标改善。
Clinical efficacy analysis of atorvastatin combined with trimetazidine in the treatment of coronary heart disease
Objective To explore the effect of atorvastatin combined with trimetazidine in the treatment of coronary heart disease.Methods 60 patients with coronary heart disease were divided into a control group and an observation group using a random number table method,each consisting of 30 patients.The control group received treatment with trimetazidine on the basis of conventional treatment,while the observation group received treatment with atorvastatin on the basis of the control group.The clinical effects,cardiac function indicators[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF)],and hemorheological indicators(whole-blood low-shear viscosity,whole-blood high-shear viscosity,plasma viscosity)were compared between the two groups.Results The total effective rate of the observation group and the control group were 93.33%and 73.33%,respectively,and the total effective rate of the observation group was significantly higher than that of the control group(P<0.05).After treatment,the plasma viscosity of the control group was(1.63±0.05)mPa·s,the whole-blood low-shear viscosity was(9.12±0.42)mPa·s,and the whole-blood high-shear viscosity was(6.15±0.24)mPa·s;the plasma viscosity of the observation group was(1.45±0.04)mPa·s,the whole-blood low-shear viscosity was(7.36±0.22)mPa·s and the whole-blood high-shear viscosity was(5.22±0.17)mPa·s;the observation group was lower than the control group(P<0.05).Compared with LVEF of(41.62±9.42)%,LVEDD of(63.30±7.21)mm and LVESD of(51.24±8.10)mm in the control group,the observation had higher LVEF of(47.69±12.08)%,and smaller LVEDD of(59.38±6.65)mm and LVESD of(46.53±7.27)mm after treatment(P<0.05).Conclusion The treatment of atorvastatin+trimetazidine in patients with coronary heart disease can achieve definite clinical efficacy and help improve the cardiac function indicators and hemorheological indicators.

AtorvastatinTrimetazidineCoronary heart diseaseEfficacy

沈慧、秦萍、张菊芳

展开 >

201800 上海市嘉定区中医医院药剂科

阿托伐他汀 曲美他嗪 冠心病 疗效

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(22)